Interim Financial Result to be Announced 24 November 2026

4 November 2026


INTERIM FINANCIAL RESULT TO BE ANNOUNCED 24 NOVEMBER
2026
DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) today
advises that its half year results for the six months to 30 September 2026 will be released on
Tuesday 24 November 2026, prior to 10am.
 
This will be followed by an Investor and Analyst conference call at 11.00am (NZST). This
investor briefing will be available via webcast by the following link:
www.virtualmeeting.co.nz/pebir26 or by phone on the following toll free numbers:
 
New Zealand – 0800 450 012
Australia – 1800 571 226
USA & Canada – 800 715 9871

Conference ID: 2639914

Questions 
Questions can be submitted online in writing via the Webcast platform or verbally via the audio
call system when prompted.  
 
If you have any queries regarding the results announcement or the conference call, please
contact Stacey Stanley on stacey.stanley@pelnz.com.  
 
 Approved for release by: 
 
Grant Gibson 
Chief Financial Officer 
Pacific Edge Ltd 
P: 0800 555 563 (NZ)
OVERVIEW
Pacific Edge: www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way
in the development and commercialization of bladder cancer diagnostic and prognostic tests
for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in
Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its
wholly owned, and CLIA certified, laboratories in New Zealand and the USA.
Cxbladder: www.cxbladder.com
Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of
urothelial cancer in patients presenting with microhematuria and those being monitored for
recurrent disease. The tests help improve the overall patient experience, while prioritizing time
and clinical resources to optimize practice workflow and improve efficiency.

2

Supported by over 20 years of research, Cxbladder’s evidence portfolio extends to more than
25 peer reviewed publications, and Cxbladder Triage is now included in the American
Urological Association’s Microhematuria Guideline. To drive increased adoption and improved
patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies
designed to generate further clinical utility evidence.
Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and
South America. In the US, the test has been used by over 5,000 urologists who have ordered
more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the
population via public healthcare and all residents have the option of buying the test online.